Overview: Carfilnat Carfilzomib 60 mg Injection contains Carfilzomib (60 mg) and is a prescription targeted anticancer medicine used in the treatment of multiple myeloma by irreversibly inhibiting proteasome activity and inducing cancer cell apoptosis. Key Benefits: – Irreversible proteasome inhibition induces apoptosis in malignant plasma cells – Effective component in multiple myeloma treatment regimens – Administered under clinical supervision Composition: Carfilzomib (60 mg) How It Works: Carfilzomib selectively and irreversibly inhibits the chymotrypsin-like activity of the 20S proteasome, disrupting protein homeostasis and triggering apoptosis in multiple myeloma cells. Usage Instructions: – Administer only under supervision of qualified healthcare professionals via intravenous infusion – Dosage and schedule determined by treatment protocol and patient condition – Not for self-administration Side Effects: – Fatigue, nausea, fever – Low blood cell counts increasing infection risk – Peripheral neuropathy, cardiac events in rare cases Precautions: – Monitor blood counts, cardiac function and blood pressure regularly during treatment – Not recommended during pregnancy or breastfeeding unless advised by a physician – Inform your doctor of all current medications Storage Instructions: – Store refrigerated between 2-8°C, protect from light, do not freeze Manufacturer: Generic Pharmaceuticals Disclaimer: To be sold by retail on the prescription of a registered medical practitioner only.